OBJECTIVE: To investigate the effect of fatigue and depression on disease progression in multiple sclerosis (MS), and the long-term prognosis of these symptoms. METHODS: 228 patients with MS were investigated for fatigue and depression with the Fatigue Severity Scale (FSS) and Center for Epidemiologic Studies Depression Scale (CES-D). These patients regularly attended the MS clinic, where disability scores and the development of secondary progression were monitored. After 10 years, the 149 patients remaining from the original cohort were asked to participate in a repeat assessment of fatigue and depression and 96 (64%) could be re-evaluated. In relapsing-remitting patients, the influence of baseline fatigue and depression on the risk of secondary progression during the following 10 years was assessed with survival analyses. In the whole patient group, we investigated the influence of baseline fatigue and depression on progression of disability at 10 years. We also investigated differences in fatigue, depression and disability scores between baseline and 10 years. RESULTS: Fatigue and depression at baseline did not predict the development of secondary progression or progression of disability. Most patients who were fatigued or depressed at baseline remained so at 10 years, and the majority of patients not experiencing these symptoms remained free of them. FSS and CES-D scores were not significantly different between baseline and 10 years, while disability scores significantly increased. CONCLUSION: Our data suggest that fatigue and depression in MS are unrelated to disease progression in MS. Fatigue and depression tend to persist at roughly the same levels over time.
OBJECTIVE: To investigate the effect of fatigue and depression on disease progression in multiple sclerosis (MS), and the long-term prognosis of these symptoms. METHODS: 228 patients with MS were investigated for fatigue and depression with the Fatigue Severity Scale (FSS) and Center for Epidemiologic Studies Depression Scale (CES-D). These patients regularly attended the MS clinic, where disability scores and the development of secondary progression were monitored. After 10 years, the 149 patients remaining from the original cohort were asked to participate in a repeat assessment of fatigue and depression and 96 (64%) could be re-evaluated. In relapsing-remitting patients, the influence of baseline fatigue and depression on the risk of secondary progression during the following 10 years was assessed with survival analyses. In the whole patient group, we investigated the influence of baseline fatigue and depression on progression of disability at 10 years. We also investigated differences in fatigue, depression and disability scores between baseline and 10 years. RESULTS:Fatigue and depression at baseline did not predict the development of secondary progression or progression of disability. Most patients who were fatigued or depressed at baseline remained so at 10 years, and the majority of patients not experiencing these symptoms remained free of them. FSS and CES-D scores were not significantly different between baseline and 10 years, while disability scores significantly increased. CONCLUSION: Our data suggest that fatigue and depression in MS are unrelated to disease progression in MS. Fatigue and depression tend to persist at roughly the same levels over time.
Authors: Marcus W Koch; Lawrence Korngut; David G Patry; Yahya Agha-Khani; Christopher White; Justyna R Sarna; Michael Yeung; V Wee Yong; Daniel Y C Heng; Gary Cutter; Luanne Metz Journal: Nat Rev Neurol Date: 2015-03-17 Impact factor: 42.937
Authors: Kyla A McKay; Helen Tremlett; John D Fisk; Tingting Zhang; Scott B Patten; Lorne Kastrukoff; Trudy Campbell; Ruth Ann Marrie Journal: Neurology Date: 2018-03-09 Impact factor: 9.910
Authors: Ruth Ann Marrie; Aaron Miller; Maria Pia Sormani; Alan Thompson; Emmanuelle Waubant; Maria Trojano; Paul O'Connor; Kirsten Fiest; Nadia Reider; Stephen Reingold; Jeffrey A Cohen Journal: Neurology Date: 2016-02-10 Impact factor: 9.910
Authors: Gabriel Bsteh; Rainer Ehling; Andreas Lutterotti; Harald Hegen; Franziska Di Pauli; Michael Auer; Florian Deisenhammer; Markus Reindl; Thomas Berger Journal: PLoS One Date: 2016-07-08 Impact factor: 3.240
Authors: Carina Sander; Paul Eling; Katrin Hanken; Jan Klein; Andreas Kastrup; Helmut Hildebrandt Journal: Front Neurol Date: 2016-09-21 Impact factor: 4.003